Optic Neuritis Treatment Market revenue to hit USD 450 Million by 2035, says Research Nester
27 sept. 2023 07h00 HE
|
Research Nester
New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The global optic neuritis treatment market size is slated to expand at ~ 5% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD...
Hematological Cancers Therapeutics Market to Reach $66.34 Billion By 2026 | Reports And Data
20 févr. 2019 05h07 HE
|
Reports And Data
High disease prevalence across the globe coupled with ongoing research and development is expected to stimulate market growth Market Size – USD 31.32 billion in 2018, Market Growth - CAGR of 9.8%,...
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS
21 mars 2018 09h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been...
Cleartronic’s (CLRI) ReadyOp™ Software Platform Used in Clinical Trial
18 sept. 2017 13h00 HE
|
Cleartronic, Inc.
BOCA RATON, Fla., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cleartronic, Inc. (OTCPINK:CLRI) announced that its wholly owned subsidiary, ReadyOp Communications, Inc., played an important role in a...
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
25 mai 2017 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
17 mars 2016 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
09 nov. 2015 16h37 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
22 avr. 2014 07h41 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
14 févr. 2014 09h49 HE
|
Elite Pharmaceuticals, Inc.
Revenues Increase by 154%, Product Development Accelerating
Conference Call Scheduled for Tuesday, February 18 at 3:00 PM ET
NORTHVALE, N.J., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Elite...
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
14 janv. 2014 13h21 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in...